SonaCare Medical’s Sonablate® Performs Prostate HIFU in Huntersville, NC

Share Article

Dr. Peretsman launches his U.S.-based prostate High Intensity Focused Ultrasound (HIFU) program in Huntersville, North Carolina by performing two HIFU procedures on the same day.

Sonablate trans-rectal HIFU probe
"Dr. Peretsman is one of our most experienced Sonablate users and has provided frequent guidance and support to SonaCare Medical over the years ..." - Dr. Mark Carol

SonaCare Medical, LLC announces the completion of two Sonablate® prostate tissue ablations performed by Dr. Samuel Peretsman. Both procedures were completed on Friday January 8th, 2016.

SonaCare Medical, headquartered in Charlotte, North Carolina was pleased to witness the launch of a local physician’s Sonablate HIFU Program. Dr. Peretsman, of Urology Specialists of the Carolinas, performed the two procedures at the Park Medical Plaza located in Huntersville, North Carolina. For almost a decade, Dr. Peretsman has worked closely with SonaCare Medical, frequently traveling to international locations where he could treat his patients. In summarizing the launch of his HIFU program, he comments “Last week, I performed the first two HIFU prostate procedures in the Carolinas, both with the recently authorized medical device, Sonablate®. With the support of HIFU Prostate Services-Carolinas in Charlotte (Huntersville), the first patient had a whole gland ablation and the second had a partial, or focal, ablation. Both men were outpatients and will return in 5 days to have catheters removed; they recovered quickly and were discharged with no need for pain medicine or concerns about urine control or erectile dysfunction. We were delighted with the launch of this technology in this region.”

Dr. Mark Carol, CEO of SonaCare Medical adds, “Dr. Peretsman is one of our most experienced Sonablate users and has provided frequent guidance and support to SonaCare Medical over the years as a proctor and as a medical director. Having a local site to showcase our technology is most welcome. It is with absolute delight that we welcome him to the growing U.S. family of Sonablate users, as well as the next HIFU Prostate Services location.”

Sonablate® is the first device to receive regulatory authorization from the FDA for the focused ultrasound ablation of prostate tissue. Since its introduction over 15 years ago, Sonablate® technology has been used around the world on nearly 15,000 patients in over 30 countries, including approximately 4,000 U.S. men who have had this procedure performed outside the U.S.

About SonaCare Medical, LLC
SonaCare Medical is a world leader in minimally invasive focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: Sonablate®, which has 510(K) clearance in the U.S. under a De Novo regulatory classification; Sonablate® 500, which has CE Marking and has obtained regulatory authorization in more than 49 countries outside the U.S.; Sonatherm® laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.

For additional information, visit


SonaCare Medical, LLC
Erica Griffith (704) 936-1834, EricaGriffith(at)SonaCareMedical(dot)com

Forward Looking Statements.
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Erica Griffith
Follow >
Visit website